Sex (male vs female) |
3.7 |
1.00 |
0.94 |
1.07 |
3 |
1.00 |
0.95 |
1.06 |
Age |
3.9 |
1.00 |
1.00 |
1.00 |
4 |
1.00 |
1.00 |
1.00 |
Medication type (buprenorphine vs
methadone) |
2.5 |
1.00 |
0.94 |
1.06 |
3.6 |
1.00 |
0.92 |
1.07 |
Last prescribed dosage (medium vs
low) |
100 |
0.57 |
0.45 |
0.71 |
100 |
0.56 |
0.43 |
0.72 |
Last prescribed dosage (high vs
low) |
100 |
0.57 |
0.44 |
0.75 |
100 |
0.54 |
0.40 |
0.73 |
Last TB test result (negative vs
positive) |
65.3 |
0.78 |
0.51 |
1.18 |
90.4 |
0.67 |
0.47 |
0.96 |
Last TB test result (not tested vs
positive) |
100 |
3.34 |
2.23 |
5.01 |
|
|
|
|
Last HIV test result (negative vs
positive) |
2.2 |
1.00 |
0.96 |
1.04 |
3.8 |
1.00 |
0.94 |
1.07 |
Last HIV test result (not tested vs
positive) |
100 |
4.44 |
3.10 |
6.35 |
|
|
|
|
Last HCV test result (negative vs
positive) |
2.7 |
1.00 |
0.92 |
1.08 |
|
|
|
|
Last HCV test result (not tested vs
positive) |
35.7 |
1.11 |
0.81 |
1.53 |
|
|
|
|
Last HBV test result (negative vs
positive) |
34.6 |
0.88 |
0.59 |
1.30 |
|
|
|
|
Last HBV test result (not tested vs
positive) |
34.3 |
1.12 |
0.80 |
1.57 |
|
|
|
|
Site (DPSPC vs DPGP5) |
37.1 |
1.17 |
0.74 |
1.85 |
4.5 |
0.99 |
0.88 |
1.12 |
Site (PNDKR vs DPGP5) |
53 |
0.82 |
0.53 |
1.26 |
27.9 |
0.92 |
0.68 |
1.24 |
Site (PNDN7 vs DPGP5) |
21.8 |
0.93 |
0.69 |
1.25 |
4.6 |
1.01 |
0.92 |
1.10 |
Site (VOND1 vs DPGP5) |
50.6 |
1.23 |
0.78 |
1.92 |
2.5 |
1.00 |
0.95 |
1.05 |
Site (VOND2 vs DPGP5) |
6.1 |
1.02 |
0.87 |
1.19 |
3.3 |
1.00 |
0.93 |
1.09 |
Admission year (2010 vs
2011–12) |
2.1 |
1.00 |
0.95 |
1.05 |
18.1 |
1.06 |
0.79 |
1.43 |
Admission year (2009 vs
2011–12) |
4 |
0.99 |
0.92 |
1.07 |
4.1 |
0.99 |
0.92 |
1.08 |
Admission year (2008 vs
2011–12) |
2.7 |
1.00 |
0.96 |
1.05 |
4.5 |
0.99 |
0.93 |
1.07 |
Admission year (2007 vs
2011–12) |
4.9 |
1.01 |
0.88 |
1.17 |
3.8 |
1.01 |
0.90 |
1.12 |
Admission year (2006 vs
2011–12) |
2.2 |
1.00 |
0.94 |
1.06 |
6.9 |
0.98 |
0.82 |
1.18 |
Admission year (2005 vs
2011–12) |
100 |
3.39 |
2.04 |
5.63 |
100 |
4.03 |
2.45 |
6.64 |